Using a combination of artificial intelligence (AI) and a computer-aided diagnosis, DCU-based startup Deciphex has developed a solution to accelerate business volume in hard-pressed pathology departments.
In other diagnostic areas, such as imaging, the digital technology means that MRI and CT scans can be read on the screen. However, the pathology is still largely manual and dependent on the physical slides prepared by a laboratory technician and then placed under a microscope for analysis by a pathologist. This takes time and makes a great deal of pressure on over-expanded pathology departments that are trying to deliver quick results to clinicians and patients desires.
A worldwide problem in the search for a solution and the Deciphex company, which was established last year, is stepping on the plate. Lar We have had the opportunity to support the widespread adoption of vak digital pathology ük that will allow pathologists to read cases on a computer monitor, not under a microscope as currently. This will help them work more efficiently and will also offer a solution for an industry that is in crisis due to high workloads and shortage of staff, sı says Deciphex co-founder and CEO Donal O çalışShea.
Medik To a large extent, we did not see the same transition in pathology, as the return on investment was not enough enough. However, the emergence of AI [artificial intelligence] changes the bid. We can use AI and deep learning to question tissue sections from biopsies to accelerate workflows and improve patient turnaround time and clinical accuracy in the clinical setting. "
The idea of Deciphex was born at the end of 2016, where O ;Shea was at a pathology conference in London. “I was talking to a US pathologist and he complained about the ever increasing expectations of service and the fact that he was a GI. [gastrointestinal] O .Shea, the pathologist routinely had normal biopsy from endoscopic procedures – endoscopies and colonoscopies – above 50 percent. Ük Since the GI pathology is approximately 20 percent of the total diagnostic workload, we immediately saw the opportunity to achieve significant productivity gains by helping to trigger this normal content. This will enable pathologists to reach problematic cases faster and more effectively.
Iyor Our software is a model of what normal content looks like, and by using this model, it can identify biopsy areas that deviate from normal. Our technology is organ agnostic and our [patented] The generalized anomaly detection approach is unique, i says OiShea.
Volume and complexity
The diagnosis volume and complexity are always increasing due to aging populations, but without any disproportionate increase in the number of pathologists being trained. Uz We see the AI as a logical way to close the gap in the next decade and beyond. .Shea has spent $ 12 billion worldwide for the diagnosis of the disease, ’he says.
The Deciphex launch product is called Patholytix and is intended for pharmaceutical companies that will use technology in clinical trials in their early stages. . It has the same core technology but different applications, tekn says O .Shea. Deciphex will enter the GI biopsy market around 2020 after legal approval. The US is the major focus and in August of this year the company announced a partnership with GI Partners of Illinois to develop the world's largest GI pathology content database for deep learning purposes. . Or GI Partners do about 14,000 biopsies per year. The Mater hospital made about 6,000. It's a completely different scale, Tamamen he said.
Starting with the pharmaceutical market is relatively straightforward, with around 10 major players dominating and O &Shea has good links in the industry. More than half have already shown interest in Patholytix, which will be officially launched this November. O .Shea said entering the clinical market would be a more challenging sale, but would become more fragmented.
Donal O yabancıhea is no stranger in the starting scene. Deciphex is the fourth company; The previous campus company Slidepath was sold to the British digital pathology group in 2009 for £ 2.5 million to Gentix. Later, Gentix was sold to Danaher Corporation in 2010 and O &Shea has worked with Danaher in several executive roles for six years, including VP of the Leia Biosystems division.
O .Shea has a history in biotechnology and is a former lecturer in DCU. CTO Mark Gregson is an expert in machine learning and pattern recognition, with over 30 years of experience in developing slide scanning and image analysis products for the co-founder, cytogenetic and pathology.
He also has experience in diagnostics and intellectual property protection. The company's COO is Mairin Raftery, who has a background in water, academia and biotechnology, and has experience in managing research programs and creating IP portfolios. Deciphex is in the process of expanding its team and currently has up to eight people. This will rise to about 25 in the next two years.
Development costs to date have been largely up to € 750,000 privately financed. . We have a large network of people who know our family tree and are willing to rank behind us, ’says O .Shea. Kazanma We have also received support from EI & E & E and with Janssen Pharmaceuticals (J & J) to accelerate the development of artificial intelligence-based workflows for the pre-clinic. we succeeded. Pathology. Or The company discusses what Shea describes as an “important financing tour”.
O .Shea agrees to enjoy the fast pace of his initial life, which he describes as ”running down a hill with a large rock chasing you’. He says that the hardest part always maintains capital requirements, and that the benefit of being older and wiser tends to be calmer and cooler and less emotional than anything else. The young founders are making very emotional investments, and they spend a lot of energy, Genç he says.
This time he asked what he was doing differently, O 39Shea says: ün Before our thought, we established a global mentality by closing down America, the largest market in the health sector worldwide. Lessons learned from past mistakes include staying in a basic message and seeing a larger picture. When I look back, I realized that we had not accumulated enough capital in the capital before. I think it's a big challenge for us because there are too many blockages in modern markets and it's easy to drown. To create a real dynamic energy about your business and to create a buzz about what you're doing, you need to use all available channels. "